Why this company should be on your Radar

Investment Breakthrough in the Approach to Parkinson's Disease Parkinson's is a devastating neurological disease that is expected to rise exponentially in the next decade. The global Parkinson's disease treatment market was estimated to be worth $5.7 billion in 2021 and is projected to exceed $12.2 billion by 2030 according to Vision Research. There hasn't been a breakthrough in treatment of Parkinson's since levodopa was put into use and no treatment can alter the course of disease for these patients Considered a wonder drug in the 1960s, Levodopa became the first-line treatment for the disease due to its action of entering the brain and helping replace the lost dopamine. A key challenge with investing in pharmaceutical companies is figuring out which disease areas might offer the best promise. One area that's ripe for investment is treatments for neurodegenerative diseases like Parkinson's. This company is working to change the slow progress in treating Parkinson's disease by developing disruptive therapies! See Why This Company Should Be on Your Radar! This message is a PAID ADVERTISEMENT for Inhibikase Therapeutics, Inc. (Nasdaq: IKT) from Interactive Offers. StockEarnings, Inc receives a fixed fee for each subscriber that clicks on a link in this email, totaling up to $1500. Other than the compensation received for this advertisement sent to subscribers, StockEarnings and its principals are not affiliated with either Inhibikase Therapeutics, Inc. (Nasdaq: IKT) or Interactive Offers. StockEarnings and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither StockEarnings nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from StockEarnings to buy or sell any security. StockEarnings has not evaluated the accuracy of any claims made in this advertisement. StockEarnings recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding Inhibikase Therapeutics, Inc. (Nasdaq: IKT) on Small Caps Daily website for additional information about the relationship between Interactive Offers and Inhibikase Therapeutics, Inc. (Nasdaq: IKT). Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click Unsubscribe. StockEarnings, Inc 33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA W: 877.6.STOCKS StockEarnings.com